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Mitosis-Independent Survivin Gene Expression In vivo and
Regulation by p53
Fang Xia and Dario C. Altieri
Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts
Abstract
Survivin is an essential mitotic gene, and this has been
speculated to reflect its primary function in development
and cancer. Here, we generated a knock-in transgenic
mouse (SVVp-GFP) in which a green fluorescent protein
(GFP) reporter gene was placed under the control of the
survivin promoter that regulates transcription at mitosis.
The expression of endogenous survivin was widespread in
mouse tissues during development and shortly after birth.
In contrast, GFP reactivity was undetectable in transgenic
mouse embryos, and was largely limited postnatally to
mitotic cells in the testes. Double transgenic mice generated
in the tumor-prone Min/+ background exhibited intestinal
adenomas that strongly expressed endogenous survivin, but
only isolated GFP-positive cells. Conversely, dysplastic
adenomas (16%) stained intensely for GFP, and revealed
focal reactivity for mutant, but not wild-type, p53. The
expression of GFP was increased by f10-fold in p53/ as
opposed to p53+/+ HCT116 colorectal cancer cells, and
reintroduction of p53 in p53/ cells abolished GFP expres-
sion. Therefore, the mitotic transcription of the survivin
gene is highly restricted in vivo , and unexpectedly nega-
tively regulated by p53. Contrary to a commonly held view,
the dominant function(s) of survivin in development and
tumor ontogeny are largely cell cycle–independent. (Cancer
Res 2006; 66(7): 3392-5)
Introduction
Survivin is a unique member of the inhibitor of apoptosis (IAP)
gene family (1) with dual functions in the control of mitosis and
preservation of cell viability (2). It has been difficult, however, to
determine which of these two roles is dominant in vivo , and
conditional knockout studies in mice produced conflicting
phenotypes with only defects of cell division (3), only exaggerated
apoptosis (4), or both (5). Insights into the function of survivin
may come from analysis of gene expression. Accordingly, the cell
cycle–dependent transcription of the survivin gene at mitosis (6),
coupled with the localization of the protein to the mitotic
apparatus and the multiple mitotic defects ensuing from survivin
loss/targeting (2), have been taken to suggest that this pathway
operates predominantly, if not exclusively, in the control of mitosis
(7, 8). Conversely, cell cycle–independent mechanisms of survivin
gene expression have been described, and linked to the inhibition
of apoptosis in various cell types (2). Elucidating how the survivin
gene is regulated in vivo is important for the indispensable role of
this pathway during development (4), and the sharp differential
expression of survivin in cancer as opposed to normal tissues,
which has been pursued for novel cancer diagnostics and
therapeutics (2).
To address these questions, we have generated a knock-in
transgenic mouse that expresses a green fluorescence protein
(GFP) reporter gene under the control of the proximal survivin
promoter (9). This DNA region has been characterized for
maintaining cell cycle periodicity at mitosis via CDE/CHR G1-
repressor elements and Sp1-type boxes (9). Unexpectedly, we found
that the expression of survivin during development and tumor
formation is largely cell cycle–independent.
Materials and Methods
Plasmid construction and generation of transgenic mice. A
mouse cDNA containing the proximal 830 nucleotide of the survivin
promoter (mS) upstream of the translational initiation codon (9) was
inserted into BamHI and HindIII sites of pBluescript II KS. The
construct was fused to a full-length cDNA encoding an enhanced GFP
(EGFP) gene at the 3V end, plus SV40 splice and polyadenylation
sequences to generate pBS-mS-830-GFP. A control pEGFP-C1 plasmid
was obtained from BD Biosciences Clontech (Palo Alto, CA). All
experiments involving animals were approved by an institutional animal
care and use committee. The pBS-mS-830-GFP targeting vector was
purified, confirmed by DNA sequencing, and microinjected (200 ng/AL)
into C57BL/6 embryos, which were transferred into pseudopregnant
females. Littermates were screened by PCR of tail genomic DNA using
primers (10 pmol) corresponding to mS (5V-AAGTTGGGCTGCAG-
GAATTCCCGCT-3V) and GFP (5V-CTTGTCGGCCATGATATAGACGTTG-
TG-3V). Colonies from three independent transgene-positive founder mice
(SVVp-GFP), or control littermates were maintained as described (10).
C57BL/6J-APCMin/J breeder mice were purchased from Jackson Labora-
tory (Bar Harbor, ME) and crossed with SVVp-GFP mice. Littermates
were screened by PCR of tail genomic DNA with primers (10 pmol)
corresponding to pMin (5V-TTCTCGTTCTGAGAAAGACAGAAGTTA-3V) and
pCOM (5V-TTTATATTCCACTTTGGCATAAGGC-3V), and double transgene-
positive mice were maintained as described (10).
RT-PCR. Total RNA was prepared from total mouse embryos collected
at E12, E14, or E18, from individual tissues isolated from 6- to 12-week-old
mice or at days 1, 3, or 5 postnatally using RNeasy Mini Kit (Qiagen, Valencia,
CA), and cDNA was synthesized using a First-Strand Synthesis System
(Invitrogen, Carlsbad, CA), according to the manufacturer’s recommenda-
tions. mRNA expression was determined by RT-PCR amplification with the
following primers: pGFP-1, 5V-AGCTGACCCTGAAGTTCATCTG-3V; pGFP-2,
5V-GATCTTGAAGTTCACCTTGATGC-3V; pM-Survivin-1, 5V-GCAGCTG-
TACCTCAAGAACTACC-3; pM-Survivin-2, 5V-TGCAGTCTCTTCAAAC-
TCTTTTTG-3; pGAPDH-1, 5V-ACGGATTTGGTCGTATTGGGCG-3;
pGAPDH-2, 5V-CTCCTGGAAGATGGTGATGG-3.
Cell culture, antibodies, and Western blotting. Cervical carcinoma
HeLa, and p53+/+ or p53/ HCT116 colorectal adenocarcinoma cells
were maintained in culture as described (11). Transient transfection
experiments were carried out using LipofectAMINE (Invitrogen), according
to the manufacturer’s recommendations. Cell cycle synchronization using
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thymidine block and release was carried out as described (6). Cells
were lysed in 50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 5 mmol/L
EDTA, 50 mmol/L NaF, 0.5% Nonidet P40 plus protease inhibitors
(Roche Applied Science), and protein-normalized extracts (40 Ag) were
processed for Western blotting, as described (11). The following antibodies
to survivin (Novus Biologicals, Littleton, CO), GFP (BD Biosciences),
mutant/wild-type p53 (ab 26, Abcam), wild-type p53 (ab16776, Abcam,
Cambridge, MA), or h-actin (Sigma-Aldrich, St. Louis, MO) were used.
Immunohistochemistry. Tissue expression of survivin, p53 or GFP was
determined with the Histostain-Plus (Zymed, South San Francisco, CA)
system after antigen retrieval by pressure cooking, as described (10).
Results and Discussion
To determine whether cell cycle regulation of survivin accounts
for its expression in development and tumor formation, we
generated a knock-in transgenic mouse that expresses GFP under
the control of an 830 nucleotide genomic fragment encoding the
core survivin promoter, and with SV40 regulatory sequences at
the 3V end (Fig. 1A). The proximal region of this promoter (f300
nucleotides) contains cell cycle elements for transcription at
mitosis (Fig. 1B), which were previously confirmed by site-directed
mutagenesis and promoter activity (9). Transfection of the pBS-
mS-830-GFP targeting construct (Fig. 1A) in synchronized HeLa
cells resulted in strict cell cycle–regulated GFP expression (Fig. 1C),
with undetectable levels in interphase, and peak activity 8 to 12
hours after thymidine release, which coincides with progression
through mitosis, by DNA content analysis and flow cytometry
(Fig. 1D). Endogenous survivin was also regulated in a cell cycle–
dependent manner peaking at mitosis in synchronized HeLa cells
(6), albeit high levels of expression were also found in interphase
and asynchronous cultures (Fig. 1C).
Confirmed transgenic mice containing the pBS-mS-830-GFP
targeting construct (SVVp-GFP) were next analyzed for the
expression of GFP and endogenous survivin during development.
Previous data suggested that survivin is abundantly and ubiquitously
found in embryonic and fetal development, progressively down-
regulated postnatally, and largely undetectable in most adult tissues
(12). Consistent with this, endogenous survivin was strongly
expressed in 14-day-old embryos of SVVp-GFP transgenic mice or
nontransgenic littermates (Fig. 2A), and was present in the thymus,
lung, spleen, and kidney at postnatal day 5 as determined by RT-PCR
(Fig. 2B). In contrast, GFP expression was undetectable in 14-day
mouse embryos of SVVp-GFP transgenic mice (Fig. 2A), and was
faintly present in brain and kidney, but not in other tissues at
postnatal day 5, as determined by RT-PCR (Fig. 2B). In developed
mouse tissues (6-12 weeks of age), GFP or endogenous survivin was
undetectable with the exception of brain, in agreement with recent
observations (13). Conversely, both GFP and endogenous survivin
were highly expressed in the testes of SVVp-GFP transgenic mice
as determined by RT-PCR (Fig. 2A) and Western blotting (Fig. 2C).
Figure 1. Requirements for mitotic survivin gene expression. A, targeting construct (pBS-mS-830-GFP). The positions of restriction sites and a translational initiation
codon (ATG ) are indicated: (B) BamHI, (H ) HindIII, (N ) Nco I, (X ) Xho I. B, proximal survivin promoter sequence. Cell cycle–regulated CDE, CHR, and Sp1-like
boxes are indicated. A putative p53-binding site is underlined. C, cell cycle periodicity. HeLa cells transfected with the pBS-mS-830-GFP targeting vector were
synchronized by thymidine block, harvested at the indicated time intervals after release, and analyzed by Western blotting. No release, thymidine-arrested cells (G1-S);
HeLa, asynchronous cultures. D, DNA content analysis. Synchronized HeLa cells were harvested at the indicated time intervals after thymidine release and
analyzed by propidium iodide staining and flow cytometry. The percentage of cells in G1 or G2-M phase is indicated for each time point. HeLa, asynchronous cultures.
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By immunohistochemistry of 8-week-old testes, GFP-positive cells in
SVVp-GFP transgenic mice were identified morphologically as
mitotic cells, preferentially at the metaphase transition (Fig. 2D,
inset , and E) whereas nontransgenic animals had no GFP reactivity
in the testes (Fig. 2F and G). Identical results were obtained with
colonies from independent SVVp-GFP founder mice.
We next studied the mitotic regulation of survivin gene
expression during tumor development, and we generated double
transgenic mice expressing SVVp-GFP on the tumor-prone Min/+
background. In this model, a mutation in the mouse homologue of
the adenomatous polyposis (APC) gene results in the formation of
multiple intestinal adenomas (14), which are histologically
characterized by epithelial hyperplasia and disorganized glandular
architecture, as determined by H&E staining (Fig. 3A). Adenomas
in double transgenic mice stained intensely for endogenous
survivin (Fig. 3B), whereas GFP reactivity was restricted to isolated
cells (Fig. 3C), and a control IgG was negative (Fig. 3D). In contrast,
2 out of 12 adenomas (16%) formed in double transgenic mice
exhibited morphologic features of dysplasia, which coincided with
extensive labeling for GFP (Fig. 3F), and focal reactivity for mutant
(Fig. 3G), but not wild-type, p53 (Fig. 3H). A control IgG gave no
staining in dysplastic adenomas (Fig. 3E).
To test a role of p53 in negatively regulating mitotic survivin
gene expression, we used p53+/+ and p53/ HCT116 colorectal
cancer cells (11). Transfection of control pEGFP resulted in the
strong expression of GFP, which was indistinguishable in p53+/+ or
p53/ cells, as determined by fluorescence microscopy (Fig. 4A)
and Western blotting (Fig. 4B). In contrast, transfection of the
SVVp-GFP targeting construct pBS-mS-830-GFP resulted in a
f10-fold increased GFP expression in p53/ as compared with
p53+/+ HCT116 cells, as determined by fluorescence microscopy
(Fig. 4A) and Western blotting (Fig. 4B). Reintroduction of wild-
type p53 in p53/ HCT116 cells largely abolished the expression
of the pBS-mS-830-GFP targeting construct, but did not affect
pEGFP reactivity (Fig. 4C).
In summary, the mitotic regulation of the survivin gene is
highly restricted in vivo , and does not account for the widespread
expression of endogenous survivin in development and tumor
formation. Our results counter a commonly held view that the
primary function of survivin is at cell division (7, 8), and argue
that survivin gene expression in vivo is largely mediated by cell
cycle–independent mechanisms. This may reflect the ubiquitous
role of survivin in apoptosis inhibition, which contributes to
tumorigenesis (15), and, at least in certain tissues, is indispens-
able for development (4). Unexpectedly, the mitotic component
of survivin gene expression is negatively regulated by p53, in a
pathway that may involve direct transcriptional silencing via
putative p53-responsive elements (16), or indirect promoter
squelching (17). Inhibition of mitotic survivin gene expression
by p53 may cooperate with checkpoint functions at the G2-M
phase, especially p53-dependent apoptosis (18), as acute loss of
survivin in dividing cells results in massive cell death (19).
Conversely, loss of p53 during tumor progression may cooperate
with cell cycle–independent mechanisms to further deregulate
Figure 2. Mitotic survivin gene expression during development. A, expression in mouse embryos. Two independent embryos (lanes 2 and 3) from SVVp-GFP
transgenic mice were harvested at E14, and analyzed by RT-PCR for expression of endogenous survivin, GFP or GAPDH. A transgene-negative embryo (lane 1), or
testes isolated from 4-week-old transgenic mice (lane 4 ) were used as controls. B, postnatal expression. Tissues isolated from SVVp-GFP transgene-positive
developed mice (6-12 weeks of age) or at day 5 postnatally (P5 1 and P5 2 ) were harvested, and analyzed for expression of endogenous survivin, GFP or GAPDH, as
determined by RT-PCR. The tissues used are: lane 1, brain; lane 2, thymus; lane 3, lung; lane 4, liver; lane 5, spleen; and lane 6, kidney. C, Western blotting.
Testes were isolated from 4-week-old nontransgenic (NT ) or transgenic (T ) mice, and analyzed by Western blotting. HCT116 cells transfected with SVVp-GFP were
used as control. D–G, immunohistochemistry. Testes from (D, E ) transgenic (T ) or (F, G ) nontransgenic (NT ) mice (4 weeks old) were stained with an antibody to GFP.
Arrows , GFP-positive cells (magnification, 200). Inset, mitotic morphology of a GFP-positive cell (magnification, 400).
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survivin gene expression in vivo , ablating mitotic checkpoint
mechanisms and promoting resistance to apoptosis of cells
traversing mitosis (19).
Acknowledgments
Received 12/20/2005; revised 2/6/2006; accepted 2/13/2006.
Grant support: NIH grants CA90917, CA78810, and HL54131.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Drs. Bert Vogelstein for generously providing HCT116 cells, Jianyuan Luo
for the p53 construct, Ron Lubet for discussion, and David S. Garlick for reviewing
histology.
Figure 3. Mitotic survivin gene expression during tumor formation.
A-H, immunohistochemistry. Intestinal adenomas without (A-D ) or with
(E-H ) dysplasia formed in Min/+-SVVp-GFP double transgenic mice were
analyzed by H&E (A), or stained with antibodies to survivin (B), GFP
(C and F ), control IgG (D and E), mutant p53 (G), or wild-type p53 (H ).
Magnification, 100. Inset, focal reactivity for mutant p53 in dysplastic
adenomas (magnification, 400).
Figure 4. Negative regulation of mitotic survivin gene expression by p53.
A, fluorescence microscopy. p53+/+ or p53/ HCT116 cells were transfected
with the targeting construct p-BS-mS-830-GFP (SVVp-GFP) or pEGFP, and
analyzed by fluorescence microscopy. The percentage of labeled cells in each
condition was: SVVp-GFP/p53+/+, 1.5%; SVVp-GFP/p53/, 10.8%; pEGFP/
p53+/+, 46.5%; pEGFP/p53/, 48.6% (n = 2). B, Western blotting. The
experimental conditions are as in (A), except that cells were harvested and
analyzed by Western blotting. C, p53 transfection. p53/ HCT116 cells
were cotransfected with a plasmid encoding wild-type p53 and pEGFP or
pBS-mS-830-GFP (SVVp-GFP), and analyzed by Western blotting.
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